Table 1.
Baseline characteristics.
| Anthropometric and metabolic data | |
|---|---|
| Age (years) | 72.9 ± 8.7 |
| Female gender (%) | 41.6 |
| Body mass index (kg/m2) | 27.0 ± 4.3 |
| CHA2DS2-VASc score# | 3 (2–4) |
| Adiponectin# (ng/mL) | 5.6 (3.2–8.6) |
| sCD40L# (ng/mL) | 49 (40–70) |
|
| |
| Cardiovascular risk factors | |
|
| |
| Hypertension (%) | 88.3 |
| Diabetes mellitus (%) | 17.9 |
| Heart failure (%) | 16.7 |
| History of stroke/TIA (%) | 14.0 |
| History of MI (%) | 23.0 |
| Metabolic syndrome (%) | 51.0 |
|
| |
| Concomitant therapies | |
|
| |
| (i) Antiplatelets (%) | 11.3 |
| (ii) ACE inhibitor/ARBs (%) | 68.1 |
| (iii) β blockers (%) | 45.1 |
| (iv) Calcium channel blockers (%) | 33.9 |
| (v) Statins (%) | 45.5 |
| (vi) Antiarrhythmic drugs (%) | 34.2 |
#Data are expressed as median and interquartile range.
sCD40L: soluble CD40 ligand, TIA: transient ischemic attack, MI: myocardial infarction, ACE: angiotensin converting enzyme, and ARBs: angiotensin receptor blockers.